Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases : A 12-Month Longitudinal Study. BOUSO J.C., JIMENEZ-GARRIDO D., ONA G., WOZNICA D., dos SANTOS R.G., HALLAK J.E.C., PARANHOS B. A., de ALMEIDA MENDES F., YONAMINE M. et al. : Phytotherapy Research, 2020. Doi : 10.1002/ptr.6639 © 2020 John Wiley & Sons, Ltd. Abstract The number of patients using cannabis for therapeutic purposes is growing worldwide. While research regarding the treatment of certain diseases/disorders with cannabis and cannabinoids is also expanding, only a few longitudinal studies have assessed the mid-term impacts of medical cannabis use on psychological variables and quality [...]
Lire la suiteCannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction Selena N. Clem, Teresa L. Bigand, Marian Wilson Pain Management Nursing, 2019, 1-5. Doi : 10.1016/j.pmn.2019.06.009 a b s t r a c t Background : Cannabis has been linked to reduced opioid use, although reasons for cannabis use among adults prescribed opioids are unclear. Aims : The purpose of this study was to determine whether motivations for cannabis use differ between adults prescribed opioids for persistent pain versus those receiving opioids as medication-assisted treatment for opioid use disorder. Design : A cross-sectional survey design was used. Participants : Adults prescribed opioids for persistent pain (n [...]
Lire la suiteBenefits and adverse effects of cannabis use among adults with persistent pain Teresa Bigand, Cristina Lee Anderson, Mary Lee Roberts, Michele Rose Shaw, Marian Wilson Nursing Outlook, 2 0 1 9 , 67, 2 2 3 -2 3 1 doi : 10.1016/j.outlook.2018.12.014. A B S T R A C T Background : Increasingly, states are legalizing cannabis for recreational use. Improved accessibility may allow adults with pain to use cannabis more liberally. Greater understanding is needed about how adults with pain perceive the effects of cannabis, particularly those who also use opioid analgesics. Purpose : To examine the perceived effects of cannabis among adults who have [...]
Lire la suiteOpioid mortality following implementation of medical marijuana programs (1999-2017) in the United States Daniel E. Kaufman, Asawer M. Nihal, Janan D. Leppo, Kelly M. Staples, Kenneth L. McCall, Brian J. Piper BioRxiv preprint, June 14, 2019. Doi : 10.1101/670059 Abstract The United States is in the midst of an opioid overdose epidemic. A prior report using the Center for Disease Control’s Wide-ranging Online Data for Epidemiologic Research (WONDER) database discovered that opioid overdoses decreased by 24.8% from 1999 to 2010 in states with medical cannabis (MC+) relative to those without (MC-). The present study evaluated any differences following MC legislation on WONDER reported opioid overdoses, [...]
Lire la suiteCannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain Megan Wildes, Teresa L. Bigand, Matthew E. Layton, , Marian Wilson Pain Management Nursing, 2019, 1-6. Doi : 10.1016/j.pmn.2019.06.014 a b s t r a c t Background : Adults with persistent pain frequently report cannabis use to help manage their symptoms. The impact of cannabis use on cognition in the presence of concurrent symptoms of depression and anxiety is poorly understood. Aims : Our study explored how cannabis use affects relationships among symptoms of depression, anxiety, and cognition. Design : A cross-sectional survey study was conducted. Settings : Surveys were distributed at outpatient clinics treating adults [...]
Lire la suiteCannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder Marian Wilson, Hannah Y. Gogulski, Carrie Cuttler, Teresa L. Bigand, Oladunni Oluwoye,Celestina Barbosa-Leiker, MaryLee A. Roberts Addictive Behaviors, 2017, 30 p. doi : 10.1016/j.addbeh.2017.10.012 Abstract Introduction : Adults in Medication-Assisted Treatment (MAT) for opioid addiction are at risk for substance use relapse and opioid overdose. They often have high rates of cannabis use and comorbid symptoms of pain, depression, and anxiety. Low levels of self-efficacy (confidence that one can self-manage symptoms) are linked to higher symptom burdens and increased substance use. The effects of cannabis use on symptom management [...]
Lire la suiteLE CBD EST-IL PSYCHOACTIF ? François-Olivier GAGNON-HÉBERT – Chercheur Postdoctoral/ Université de Moncton, Canada La Lettre du RESPADD, 2019, 36, 4-5 https://www.respadd.org/lettre-n36-octobre-2019/ Il semble y avoir une véritable résurgence du cannabis dans les débats publics à l’échelle internationale depuis quelques années. Cette plante cultivée depuis les premiers balbutiements des sociétés humaines néolithiques grégaires (Warf 2014) ne laisse personne indifférent. Bien que les apologistes et les détracteurs de l’usage de la plante ne s’entendent généralement sur aucun point, tous s’entendent sur la réalité suivante : il s’agit d’une question fort complexe et épineuse. Au-delà des débats moraux et sociétaux, il n’en demeure pas moins que le cannabis [...]
Lire la suiteEtats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020 https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/ GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]
Lire la suitePharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects Friederike Holze, Urs Duthaler, Patrick Vizeli, Felix Müller, Stefan Borgwardt, Matthias E. Liechti British Journal of Clinical Pharmacology, March 2019 Doi : 10.1111/bcp.13918 Aims : The aim of the present study was to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD) that was developed for clinical use in research and patients. Method : LSD (100 μg) was administered in 27 healthy subjects using a placebocontrolled, double‐blind, cross‐over design. Plasma levels of LSD, nor‐LSD, and 2‐ oxo‐3‐hydroxy‐LSD (O‐H‐LSD) and subjective drug effects were assessed [...]
Lire la suiteEffect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults Anthony N. Nicholson, MD, PhD, Claire Turner, BSc, Barbara M. Stone, PhD, and Philip J. Robson, MDy Journal of Clinical Psychopharmacology, 2004, Volume 24, Number 3, 305-313. Doi : 10.1097/01.jcp.0000125688.05091.8f Abstract : The effects of cannabis extracts on nocturnal sleep, earlymorning performance, memory, and sleepiness were studied in 8 healthy volunteers (4 males, 4 females; 21 to 34 years). The study was double-blind and placebo-controlled with a 4-way crossover design. The 4 treatments were placebo, 15 mg D-9-tetrahydro-cannabinol (THC), 5 mg THC combined with 5 mg cannabidiol (CBD), and 15 mg [...]
Lire la suite